Silence Therapeutics has issued an update to its announcement on 9 January regarding the acquisition of a minority stake in Arrowhead Pharmaceuticals, Inc.
Silence says it has today filed a schedule 13D with the US Securities and Exchange Commission. Following additional purchases made by the company since 9 January, the schedule 13D sets out that Silence, as at today, directly owns 6,831,359 common shares of Arrowhead, representing 9.21% of the outstanding share capital of Arrowhead.
In aggregate, Silence has paid a total consideration of $11.3 million to acquire the 6,831,359 common shares.
At 2:28pm: (LON:SLN) Silence Therapeutics PLC share price was -1.37p at 101.63p